Teva Pharmaceutical Industries has formed a Global Specialty Medicines (GSM) group under the leadership of Rob Koremans, who becomes its President and CEO. He will continue to serve on Teva’s Executive Committee and report to Jeremy Levin, President and CEO of Teva Pharmaceutical Industries.
The new GSM Group combines Teva’s strong local presence in high-quality generics with its global scale and capabilities in specialist, said Levin. It will work with the company’s regional generics teams and establish a single, differentiated Teva presence in the market.
Dipankar Bhattacharjee, formerly Senior Vice President Western Europe, has been promoted to President and CEO of Generics Europe.
As part of the changes, Larry Downey, formerly Executive Vice President of Teva US Brands, has been appointed President, North America Specialty Medicines, reporting to Koremans.
Koremans began his career at Sanofi SA in marketing and sales roles, and in 1993 moved to Serono Group where he was appointed Vice-President, Europe in 1998. From 2000 to 2007, he was an executive board member of specialist pharmaceuticals group Grunenthal.
In 2009 he joined the Sanofi group as CEO of Zentiva and as Senior Vice President, Generics Europe.
Koremans joined Teva in 2012 as President and CEO of Teva Europe.
Bhattacharjee joined Teva as General Manager in 2009. Prior to this he worked at Bausch + Lomb for 15 years in various senior roles, including Vice President Commercial in both Europe and Asia-Pacific regions and Corporate Vice President and President, Asia Pacific Region. He began his career at Nestlé and Bank of America.
Downey joined Teva in 1995 as part of the creation of Teva Marion Partners. He has served in various senior roles, most recently as Executive Vice President of Teva US Brands.
Prior to joining Teva, he held several management positions in finance, marketing, and business development at Marion Laboratories, the predecessor to Sanofi.
